Outcome
    Moderate Evidence

    Huperzine A for Enhanced Memory Formation

    Memory benefits are documented in dementia trials and one adolescent study; healthy adult evidence is thin.

    Overview

    Memory benefits are documented in dementia trials and one adolescent study; healthy adult evidence is thin.

    Verdict

    Mixed evidence

    How It Works

    Prolonged acetylcholine availability supports hippocampal encoding and consolidation of new memories.

    Dosing & Protocol

    Typical dose

    Recommended dose
    50-200 mcg/day huperzine A with food; the memory trial in adolescents used 100 mcg twice daily
    Expected timeframe
    4 weeks

    Protocol

    form
    Isolated alkaloid, pharmacologically a cholinesterase inhibitor
    duration
    4 weeks, then reassess; cycle rather than use continuously
    co factor
    Take with food. Evidence is mixed and rests on very little. Acetylcholine is central to memory encoding, and cholinesterase inhibition is the established mechanism of dementia drugs, so the rationale is sound. The direct evidence in healthy people is one small Chinese trial in adolescents reporting improved memory and learning performance with 100 mcg twice daily over four weeks - a single study, small, and not replicated in adults. Trials in Alzheimer disease show cognitive improvements but in a population with cholinergic degeneration. Between these sits a gap: no good evidence that huperzine improves memory formation in healthy adults.
    titration
    Increase to 100 mcg twice daily if tolerated - the dose used in the adolescent memory study. Do not exceed 400 mcg/day
    starting dose
    50 mcg once daily with food

    Evidence

    What the studies say

    Beyond dementia trials, an older study in adolescents reported improved memory task performance. Rigorous replication in healthy adults is lacking.

    Efficacy and safety of the natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis

    Score: 7/10
    2009
    meta_analysis
    n=733

    Wang BS, Wang H, Wei ZH +3 more

    Huperzine A improved MMSE by roughly 2.8 points and ADL scores versus placebo.

    View source

    Safety

    Caveats

    This is a drug-like compound with drug-like risks. Safety ceiling: do not exceed 400 mcg/day, and never combine with prescribed cholinesterase inhibitors - additive cholinergic effects can cause bradycardia, seizures, bronchospasm and cholinergic crisis. Avoid with beta-blockers, anticholinergic medicines and neuromuscular blockers; stop two weeks before surgery and inform your anaesthetist. Contraindicated in epilepsy, asthma or COPD, peptic ulcer disease, bradycardia or heart block, and urinary obstruction. Nootropic stacks often combine huperzine with other cholinergics such as alpha-GPC or citicoline, which compounds the risk. Common effects are nausea, sweating, vivid dreams, cramping and diarrhoea. No safety data in pregnancy or breastfeeding - avoid in both, and in children, despite the adolescent trial. Long-term safety beyond a year is unknown, hence the common practice of cycling.

    Less likely to help if

    Healthy adults, in whom memory benefit has not been demonstrated beyond one small unreplicated study.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.